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Lucrezia Colonna, Emanuela I. Sega, Robert S. NegrinNaturally occurring regulatory T cells (Treg) are order to minimize graft rejection. The donor-derived
T cells with pivotal immunomodulatory capabilities.
Treg cells express CD4, high levels of the IL-2 receptor
CD25, and the Treg-specific transcription factor
Foxp3, that was previously shown to be sufficient to
confer immunosuppressive ability upon introduction
into nonregulatory T cells [1,2]. Natural Treg develop
in the thymus and are subsequently exported in the
periphery. Induced Treg develop in the periphery
from naive CD41 T cells following T cell receptor
(TCR) triggering in the presence of TGF-b signaling
[3]. Treg were first described in murine models for hu-
man disease following the observation that depletion of
CD251 cells lead to many different autoimmune con-
ditions, whereas reconstitution with CD41CD251
cells restored tolerance in the recipient animals [4].
It is now apparent that Treg cells are involved in the
control of many adaptive immune processes, either
directed against self or against pathogenic agents [5].
Indeed, mutations affecting the expression and/or
function of Foxp3 result in a number of autoimmune
dysfunctions in both human patients [6] and mice [7].
More recently, Treg have been used to prevent graft
rejection in different transplantation settings, and have
shown promising results in murine models for solid or-
gan as well as hematopoietic cell transplantation (HCT)
[8-17]. Allogeneic HCT is an effective treatment
for many hematopoietic diseases such as leukemia,
lymphoma, and myelodysplastic syndromes. Donor
derived bonemarrow cells or granulocyte-colony stimu-
lating factor (G-CSF) mobilized peripheral blood stem
cells (PBSCs) are infused in the patient following a che-
motherapy and/or radiation based conditioning regi-
men, which is aimed to both target malignant cells and
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also contain a percentage of mature T cells. The latter
serve multiple beneficial purposes, such as sustaining
the engraftment process, replenishing the adaptive im-
mune system to protect against infection, and recogniz-
ing and eliminating residual malignant host cells (called
graft-versus-tumor effect [GVT]).
A major complication of HCT is graft-versus-host
disease (GVHD), where alloreactive donor-derived
T cells infiltrate and injure target organs such as the
liver, gut, and skin. Although immunomodulation is
necessary to control the adverseGVHDreaction, an ef-
fective immune response is required for successful tu-
mor eradication. The traditional approach to GVHD
prevention and/or treatment is immunosuppressive
therapy, which predisposes the transplanted patients
to high risk of infections, impairs the T cell-mediated
antitumor response, and may interfere with the physi-
ological growth of younger patients. Thus, it is of cru-
cial importance to uncover alternative therapeutic
strategies to be coupled to allogeneic HCT for im-
proved control of GVHD and maintenance of GVT.
Recently, our andother laboratorieshave shownthat
freshly isolated natural Treg as well as in vitro expanded
Treg cells can prevent lethal GVHD induced by donor-
derived conventional T cells (CD41 and CD81T cells;
Tcon) following allogeneic bonemarrow transplantation
(BMT), inmultiplemodels across bothmajor andminor
histocompatibility barriers [11-17]. Furthermore, when
cotransferred into recipient mice with established
leukemia or lymphoma, Treg cells were shown to
suppress Tcon cell proliferation and prevent lethal
GVHD, while preserving GVT activity [11,16,17].
In vivo bioluminescent imaging [18] has been uti-
lized in order to visualize the patterns of homing and
proliferation of luciferase1 Treg and Tcon in vivo. These
studies demonstrated that both Treg [19] and Tcon [20]
cells must first traffic to nodal sites to become activated,
proliferate, and exploit their biological function. Nota-
bly, GVHDsuppression is restricted to theTreg fraction
expressing the lymphoid homing molecule CD62L1
(l-selectin), while CD62L2 Treg largely lacked protec-
tive capacity [21,22]. CD62L expression was associated
with accumulation of Treg cells in the spleen and
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Treg-mediated suppression of Tcon proliferation occurs
at the priming sites of alloreactive Tcon. However, Treg
seem to also exert their suppressive action in situ by
infiltrating GVHD target organs, because Treg lacking
the chemokine receptor CCR5 (whose ligands are
expressed at the sites of inflammation during ongoing
GVHD) were shown to be far less protective than
wild-type Treg [23].
Previous work has demonstrated the critical role of
recipient antigen-presenting cells (APCs) for GVHD
induction. APCs are critical for Treg activation and
suppressive activity, as Treg cells need to be of donor
origin in order to confer survival benefit, whereas
host-derivedTreg lack protective potential [13] in ama-
jor mismatch model. Indeed, several in vitro studies
have unveiled the importance of APC-Treg interaction
for Treg function [24-26].
Mechanistically, natural Treg-mediated protection
was shown to be partly dependent on IL-10 produc-
tion in a major mismatch model [13]. Additionally, an-
other important effector molecule for Treg activity has
been identified as the TNF-R family member CD30
[27]. CD30 upregulation occurs following allogenic
stimulation of Treg in vitro and in vivo [27], and follow-
ing T cell activation in general. Notably, CD30 knock-
out Treg cells were shown to be far less potent in
inhibiting GVHD compared to their wild-type coun-
terparts [27]. The ligand for CD30 (CD30L) is ex-
pressed on thymic epithelial cells (TECs), APCs,
activated T cells, neutrophils, eosinophils, and resting
B cells. Early blockade of the CD30/CD30L axis fol-
lowing HCT did not affect Treg trafficking to lym-
phoid organs, but impaired their expansion and was
associated with decreased Tcon apoptosis, suggesting
that CD30 signaling onTreg is important for their pro-
liferation and/or survival, and that the impact of Treg
cells on Tcon-cell expansion following BMT is at least
in part mediated by induction of allogeneic T cell ap-
optosis. Late CD30L blockade did not ameliorate
GVHD, indicating that GVHD suppression requires
an intervention during the early phases of Tcon activa-
tion occurring at the priming sites. CD101 can serve as
an additional useful marker for the purification of mu-
rine Treg cells with the highest suppressive potential
for GVHD suppression in vivo [28], although the spe-
cific function and the identity of the CD101 ligand are
currently unknown.
Treg represent only a small fraction of peripheral
CD41T cells (5%-10%); therefore, the potential clin-
ical use of regulatory T cells is limited by their low
number. To achieve higher numbers of Treg cells
that may be required for clinical applications, several
different expansion strategies have been employed.
One strategy takes advantage of the fact that IL-2 is
a critical growth factor for Treg, yet they do not pro-
duce this cytokine [29]. Treg survival depends entirelyon the exogenous addition of IL-2 [30,31]. Also,
important for Treg expansion and survival is signaling
through CD3 and CD28 receptors [32,33]. The
combination of high dose IL-2 and anti-CD3/CD28
coated microbeads is one of the most common ap-
proaches to expand Treg ex vivo, resulting in a pool
of Treg that maintain a diversified repertoire (poly-
clonal Treg) [14,34-37]. This protocol was used by
different research groups to expand both murine and
human Treg with an expansion efficiency from ten to
hundreds fold [34,35,38,39]. Expanded Treg can be
used in vivo to reduce GVHD where CD41CD251
cells expanded ex vivo in the presence of immobilized
anti-CD3 antibodies and 100 U/mL IL-2, when ad-
ministered in an animal model of GVHD resulting
in an increase in the median survival of mice from 10
days in control mice to 72 days [14].
The purity of the starting Treg pool is of high con-
cern during the expansion protocol, as even a small
amount of contaminating effector cells can be expanded
under these culturing conditions and, eventually, out-
grows the Treg population [40]. Several studies have
shown that the addition to the culture of rapamycin,
a well-known immunosuppressant, suppresses effector
T cell proliferation conferring a selective advantage
on Treg proliferation [41-43]. Other studies have
suggested that by starting the expansion with the
CD45RA1 fraction of CD41CD251 cells or the
CD62L1 fraction, a homogeneous Treg population
can be obtained [44,45]. In addition, Shevach’s group
[46] identified a unique set of cell surface markers
(CD121a/CD121b and LAP) expressed only on
Foxp31 Treg that can be used to separate the expanded
Foxp31 Treg cells from the non-Foxp3
1 cells.
Antigen-specific Treg expansion using peptide
pulsed DC [47] or tetramer sorting [48] is a more tech-
nically challenging strategy than the polyclonal expan-
sion, but presumably will allow for a decreased
number of Treg needed for therapy. Bluestone’s group
was able to expand an islet peptide-mimic reactive
Treg clone from a polyclonal population of NOD Treg
by replacing the anti-CD3 mAb on coated beads with
recombinant MHC class II molecules presenting an is-
let peptide-mimic [49]. Alternatively, antigen-specific
Treg capable of recognizing allogeneic antigens can be
obtained by culturing purified Treg in the presence of
recipient type APC and IL-2 [15,50,51]. Using this
strategy, Trenado et al. [52] were able to generate
Treg that were more efficient in providing protection
from GVHD than the polyclonal expanded Treg [52].
Recent studies have indicated a direct correlation
between the DNA methylation/demethylation of the
CpG motif within the 50 untranslated region of the
foxp3 promoter and the stability of Foxp3 expression
[53]. Thus, natural Treg are completely demethylated
at this evolutionarily conserved region called ‘‘Treg -
specific demethylated region’’ (TSDR). In contrast,
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1CD252 cells by
TCR stimulation in the presence TGF-b and IL-2 are
only partially demethylated at the TSDR region, sug-
gesting a transient Foxp3 expression and, subsequently,
a loss of Foxp3 expression following TGF-bwithdrawal
[53]. Based on these results, Choi et al. designed a novel
Treg expansion strategy in which hypomethylating
agents, decitabine and azacitidine, were used to generate
functionalFoxp31Treg fromCD4
1CD252Tcells [54].
Decitabine treatment of CD41CD252 T cells stimu-
lated with anti-CD3/CD28 beads and low-dose IL-2
induced Foxp3 expression in 60% to 70% of cells, and
Foxp3 expression was maintained even 7 days after the
decitabine treatment [54].
The molecular basis of Treg cell suppressive
activity is still unclear. A better understanding of
Treg biology will allow the optimization of innovative
preclinical protocols for the enhancement of Treg im-
munomodulatory activity in vivo, while preserving
the Tcon-mediated GVT effect following allogeneic
HCT. The ultimate goal is to translate the insights ob-
tained from these preclinical studies into novel thera-
peutic strategies, with the idea of minimizing the use
of immunosuppressive drugs following HCT. Indeed,
the cotransfer of Treg cells into lethally irradiatedmice,
recipient of T cell-depleted bone marrow and Tcon
cells, resulted in enhanced immune reconstitution
and increased survival following challenge with
viral pathogens, without interfering with the Tcon-
mediated tumor clearance. These preclinical models
have been adapted to ongoing clinical trials assessing
the efficacy of human Treg in the clinic [55,56] (R.S.
Negrin, unpublished results). Brunstein et al. [55] re-
cently reported the results of the first clinical trial
with umbilical cord blood (UCB)-derived in vitro ex-
panded Treg in patients receiving a nonmyeloablative
double UCB transplant. Although Treg infusion (up
to 30  105/kg on days 11 and 115) mildly delayed
but did not significantly ameliorate GVHD compared
to historical controls, Treg immunotherapy proved
to be safe, increased the number of circulating
CD41Foxp31 cells, and facilitated mixed chimerism.
It remains possible that prolonged in vitro expansion
partly affected the suppressive potential of the cultured
Treg. Thus, it will be important to identify the optimal
culture conditions as wells as the maximum tolerated
dose of in vitro expandedTreg in human patients follow-
ing transplantation, in order to plan the future studies
that will allow a thorough evaluation of the true impact
of Treg engraftment and GVHD suppression.
Furthermore, the results of a phase I/II clinical
trial evaluating the impact of freshly isolated Treg cells,
on GVHD prevention and immunologic reconstitu-
tion was recently reported byMartelli’s group in Peru-
gia, Italy [56]. Following a conditioning regiment
including total-body irradiation (TBI) and chemo-
therapy, 22 patients received CD41CD251 freshlyisolated donor Treg 3 days before administration of
highly purified CD341 cells together with mature
Tcon, at a Treg:Tcon ratio of 1:1.5. Notably, no post-
transplant GVHD prophylaxis was used in this study.
Although some patients succumbed to transplant-
related opportunistic infections (6/22), most patients
engrafted (20/22) and displayed long lasting full
donor-type chimerism. Strikingly, Treg immunother-
apy not only improved immune recovery, but most
patient did not present any manifestation of GVHD
following Tcon administration (17/20), whereas 2 pa-
tients developed mild grade I cutaneous GVHD, and
only 1 patient developed grade III GVHD. Thus,
Treg immunotherapy rendered the administration of
a high dose of Tcon tolerated for the first time reported
in the setting of haploidentical transplantation, provid-
ing sustained protection from GVHD and improved
immune reconstitution. Another approach has been
to expand Treg in vivo utilizing differences between
conventional and regulatory T cell biology. The first
attempt combined CD41 cell donor lymphocyte infu-
sions with low-dose IL-2, which resulted in a preferen-
tial expansion of Treg in patients [57]. This strategy
and others may result in the selective proliferation of
Treg in certain clinical situations, for example, chronic
GVHD.
If successful, further understanding of Treg biology
may be extended to additional clinical applications,
such as tolerance induction in the context of severe au-
toimmune diseases and/or solid organ transplantation.ACKNOWLEDGMENTS
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